tetano
Editor, Senior Moderator
Nat Commun. 2017 Jan 19;8:14234. doi: 10.1038/ncomms14234.
[h=1]A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.[/h] Chai N[SUP]1[/SUP], Swem LR[SUP]1[/SUP], Park S[SUP]2[/SUP], Nakamura G[SUP]3[/SUP], Chiang N[SUP]3[/SUP], Estevez A[SUP]4[/SUP], Fong R[SUP]4[/SUP], Kamen L[SUP]5[/SUP], Kho E[SUP]5[/SUP], Reichelt M[SUP]6[/SUP], Lin Z[SUP]2[/SUP], Chiu H[SUP]7[/SUP], Skippington E[SUP]8[/SUP], Modrusan Z[SUP]9[/SUP], Stinson J[SUP]9[/SUP], Xu M[SUP]2[/SUP], Lupardus P[SUP]4[/SUP], Ciferri C[SUP]4[/SUP], Tan MW[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza B virus (IBV) causes annual influenza epidemics around the world. Here we use an in vivo plasmablast enrichment technique to isolate a human monoclonal antibody, 46B8 that neutralizes all IBVs tested in vitro and protects mice against lethal challenge of all IBVs tested when administered 72 h post infection. 46B8 demonstrates a superior therapeutic benefit over Tamiflu and has an additive antiviral effect in combination with Tamiflu. 46B8 binds to a conserved epitope in the vestigial esterase domain of hemagglutinin (HA) and blocks HA-mediated membrane fusion. After passage of the B/Brisbane/60/2008 virus in the presence of 46B8, we isolated three resistant clones, all harbouring the same mutation (Ser301Phe) in HA that abolishes 46B8 binding to HA at low pH. Interestingly, 46B8 is still able to protect mice against lethal challenge of the mutant viruses, possibly owing to its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).
PMID: 28102191 DOI: 10.1038/ncomms14234
[PubMed - in process]
[h=1]A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.[/h] Chai N[SUP]1[/SUP], Swem LR[SUP]1[/SUP], Park S[SUP]2[/SUP], Nakamura G[SUP]3[/SUP], Chiang N[SUP]3[/SUP], Estevez A[SUP]4[/SUP], Fong R[SUP]4[/SUP], Kamen L[SUP]5[/SUP], Kho E[SUP]5[/SUP], Reichelt M[SUP]6[/SUP], Lin Z[SUP]2[/SUP], Chiu H[SUP]7[/SUP], Skippington E[SUP]8[/SUP], Modrusan Z[SUP]9[/SUP], Stinson J[SUP]9[/SUP], Xu M[SUP]2[/SUP], Lupardus P[SUP]4[/SUP], Ciferri C[SUP]4[/SUP], Tan MW[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza B virus (IBV) causes annual influenza epidemics around the world. Here we use an in vivo plasmablast enrichment technique to isolate a human monoclonal antibody, 46B8 that neutralizes all IBVs tested in vitro and protects mice against lethal challenge of all IBVs tested when administered 72 h post infection. 46B8 demonstrates a superior therapeutic benefit over Tamiflu and has an additive antiviral effect in combination with Tamiflu. 46B8 binds to a conserved epitope in the vestigial esterase domain of hemagglutinin (HA) and blocks HA-mediated membrane fusion. After passage of the B/Brisbane/60/2008 virus in the presence of 46B8, we isolated three resistant clones, all harbouring the same mutation (Ser301Phe) in HA that abolishes 46B8 binding to HA at low pH. Interestingly, 46B8 is still able to protect mice against lethal challenge of the mutant viruses, possibly owing to its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).
PMID: 28102191 DOI: 10.1038/ncomms14234
[PubMed - in process]